LAGλ1: A clinically relevant drug resistant human multiple myeloma tumor murine model that enables rapid evaluation of treatments for multiple myeloma

International Journal of Oncology

Volumn 28, Issue 6, 2006, Pages 1409-1417

  Campbell, Richard A ^a   Manyak, Steven J ^a   Yang, Honghao H ^b   Sjak Shie, Nelida N ^c   Chen, Haiming ^a   Gui, Dorina ^e   Popoviciu, Laura ^e   Wang, Cathy ^a   Gordon, Melinda ^a   Pang, Shen ^d   Bonavida, Benjamin ^e   Said, Jonathan ^e   Berenson, James R ^a  

^a INSTITUTE FOR MYELOMA AND BONE CANCER RESEARCH   (United States)

^b Pacific Shores Medical Group   (United States)

^c Center for Cancer Care and Research   (United States)

^d UCLA SCHOOL OF DENTISTRY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Animal model; Multiple myeloma; Murine model; SCID mouse

Indexed keywords

IMMUNOGLOBULIN G;

ANIMAL; ARTICLE; BIOPSY; BLOOD; BONE MARROW; CELL DIVISION; DRUG RESISTANCE; FLOW CYTOMETRY; HINDLIMB; HUMAN; MOUSE; MOUSE MUTANT; MULTIPLE MYELOMA; PATHOLOGY; SKELETAL MUSCLE; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; BIOPSY; BONE MARROW; CELL DIVISION; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; HINDLIMB; HUMANS; IMMUNOGLOBULIN G; MICE; MICE, SCID; MULTIPLE MYELOMA; MUSCLE, SKELETAL; TRANSPLANTATION, HETEROLOGOUS;

EID: 33747121704     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.28.6.1409     Document Type: Article

References (31)

1. Alsina M, Boyce BF, Devlin RD, et al: Development of an in vivo model of human multiple myeloma bone disease. Blood 87: 1495-1501, 1996.
2. Bellamy WT, Mendibles P, Bontje P, et al: Development of an orthotopic SCID mouse-human tumor xenograft model displaying the multidrug-resistant phenotype. Cancer Chemother Pharmacol 37: 305-316, 1996.
3. null mice. Cancer Sci 95: 564-568. 2004.
4. Mitsiades CS, Mitsiades NS, Bronson RT, et al: Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications. Cancer Res 63: 6689-6696, 2003.
5. null (NOG) mice. Biochem Biophys Res Commun 313: 258-262, 2004.
6. Reme T, Gueydon E, Jacquet C, et al: Growth and immortalization of human myeloma cells in immunodeficient severe combined immunodeficiency mice: a preclinical model. Br J Haematol 114: 406-413, 2001.
7. Urashima M, Chen BP, Chen S, et al: The development of a model for the homing of multiple myeloma cells to human bone marrow. Blood 90: 754-765, 1997.
8. Ashmann EMJ, van Tol MDJ, Oudemann-Gruber J, et al: The SCID mouse as a model for multiple myeloma. Br J Haematol 89: 319-327, 1995.
9. Feo-Zuppardi J, Taylor CW and Iwato K: Long-term engraftment of fresh human myeloma cells in SCID mice. Blood 80: 2843-2850, 1992.
10. Huang SY, Tien HF, Su FH and Hsu SM: Nonirradiated NOD/SCID-human chimeric animal model for primary human multiple myeloma. Am J Pathol 164: 747-756, 2004.
11. Kyoizumi S, Baum CM, Kaneshima H, McCune JM, Yee EJ and Namikawa R: Implantation and maintenance of functional human bone marrow in SCID-hu mice. Blood 79: 1704-1711, 1992.
12. Namikawa R, Ueda R and Kyoizumi S: Growth of human myeloid leukemias in the human marrow environment of SCID-hu mice. Blood 82: 2526-2536, 1993.
13. Pilarski LM, Hipperson G, Seeberger K, et al: Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD/SCID mice. Blood 95: 1056-1065, 2000.
14. Radl J: Multiple myeloma and related disorders. Lessons from an animal model. Pathol Biol (Paris) 47: 109-114, 1999.
15. Yaccoby S and Epstein J: The proliferative potential of myeloma plasma cells manifest in the SCID-hu host. Blood 94: 3576-3582, 1999.
16. Yaccoby S, Barlogi B and Epstein J: Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood 92: 2908-2913, 1998.
17. Yata K and Yaccoby S: The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells. Leukemia 18: 1891-1897, 2004.
18. LeBlanc R, Catley LP, Hideshima T, et al: Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 62: 4996-5000, 2002.
19. Frost P, Moatomed F, Hoang B, et al: In vivo anti-tumor effects of the mTOR inhibitor, CCI-779, against human multiple myeloma cells in a xenograft model. Blood 104: 4181-4187, 2004.
20. Lentzsch S, Rogers MS, LeBlanc R, et al: S-3-Aminophthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice. Cancer Res 62: 2300-2305, 2002.
21. Richardson PG, Barlogie B, Berenson J, et al: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348: 2609-2617, 2003.
22. Dimopoulos MA and Kyle RA: Treatment of multiple myeloma. In: Biology and Management of Multiple Myeloma. Berenson JR (ed). Humana Press, New Jersey, pp137-151, 2004.
23. Sirohi B and Powles R: Multiple myeloma. Lancet 363: 875-887, 2004.
24. Berenson JR, Yang HH, Sadler K, et al: Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 24: 937-944, 2006.
25. Hussein MA, Wood L, His E, et al: A phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients. Cancer 95: 2160-2168, 2002.
26. Orlowski RZ, Voorhees PM, Garcia RA, et al: Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 105: 3058-3065, 2005.
27. Basu S, Ma R, Boyle PJ, et al: Apoptosis of human carcinoma cells in the presence of potential anti-cancer drugs: III. Treatment of Colo-205 and SKBR3 cells with: cis-platin, tamoxifen, melphalan, betulinic acid, L-PDMP, L-PPMP, and GD3 ganglioside. Glycoconj J 20: 563-577, 2004.
28. Furrer M, Altermatt HJ, Ris HB, et al: Lack of antitumour activity of human recombinant tumour necrosis factor-alpha, alone or in combination with melphalan in a nude mouse human melanoma xenograft system. Melanoma Res 7: S43-S49, 1997.
29. Uneda S, Hata H, Matsuno F, et al: A nitric oxide synthase inhibitor, N(G)-nitro-l-arginine-methyl-ester, exerts potent antiangiogenic effects on plasmacytoma in a newly established multiple myeloma severe combined immunodeficient mouse model. Br J Haematol 120: 396-404, 2003.
30. Berenson JR, Ma HM and Vescio R: The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma. Semin Oncol 28: 626-633, 2001.
31. Ma MH, Yang HH, Parker K, et al: The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 9: 1136-1144, 2003.